Annovis Announces Pricing of $21.0 Million Public Offering

The financing includes accompanying warrants to purchase up to 21,000,000 additional common shares at $1.00 per share.

Rhea-AI Summary

Annovis Bio (NYSE: ANVS) priced an underwritten public offering expected to raise approximately $21.0 million in gross proceeds before expenses.

The offering includes 19,000,000 common shares and pre-funded warrants for up to 2,000,000 shares, plus accompanying warrants for up to 21,000,000 shares. Share-and-warrant packages cost $1.00; pre-funded-warrant packages cost $0.9999, with a $0.0001 exercise price. Accompanying warrants are immediately exercisable at $1.00 per share and expire five years after issuance. Gross proceeds exclude potential accompanying-warrant exercise proceeds. Annovis expects closing on or about November 6, 2026 and intends to use net proceeds for buntanetap clinical studies in Alzheimer’s and Parkinson’s diseases, plus working capital and general corporate purposes.

2 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Offering proceeds are expected to total approximately $21.0 million gross, excluding potential accompanying-warrant exercise proceeds. 41% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Annovis intends to fund buntanetap clinical development in Alzheimer’s and Parkinson’s diseases with net proceeds.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Issuance of 19,000,000 common shares at $1.00 per share-and-warrant package dilutes existing holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrants for up to 2,000,000 shares add dilution; packages cost $0.9999, with $0.0001 exercise prices.
• Minor point. Forward-looking: it has not happened yet and may not happen.Accompanying warrants for up to 21,000,000 shares add potential dilution; immediately exercisable at $1.00, expiring after five years.

News Explained

The priced deal is still awaiting closing; if completed, Annovis sells the common shares and warrants, and shares issued at closing or on warrant exercise expand the share count and reduce existing holders’ percentage ownership.

Argus 15 min delay 12 alerts

-24.79% vs previous close $0.9100 last price 62.5x rel. volume Open Argus

Details

Market move: ANVS -24.79% vs previous close. $21.0 million public offering

$0.87 – $0.98 Day Range

$38.84M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for ANVS is 24.79% below the previous close. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $0.91. Relative volume is exceptionally heavy at 62.5x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Expected gross proceeds: approximately $21.0 million Common shares offered: 19,000,000 shares Pre-funded warrants: up to 2,000,000 shares +5 more

Expected gross proceeds

approximately $21.0 million

Before underwriting discounts, commissions, and other offering expenses; excludes potential warrant exercise proceeds

Common shares offered

19,000,000 shares

Underwritten public offering

Pre-funded warrants

up to 2,000,000 shares

Offered in lieu of common stock to certain investors

Accompanying warrants

up to 21,000,000 shares

Warrants accompanying the offered shares or pre-funded warrants

Combined offering price

$1.00

Per common share and accompanying warrant

Pre-funded warrant package price

$0.9999

Per pre-funded warrant to purchase one share and accompanying warrant

Accompanying warrant exercise price

$1.00 per share

Warrants are exercisable immediately upon issuance

Accompanying warrant term

five years

Expiration after issuance

Previous Offering Reports

2 past events · Latest: May 20

Same Type 2 events

1. May 20

   public offering

   24h Move

   +5.2%

   Priced common shares with accompanying warrants, targeting $15.0 million in gross proceeds.

2. Apr 09

   underwritten offering

   24h Move

   -29.6%

   Priced 5,263,156 common shares and warrants at $1.90, targeting $10 million in gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, form s-3

4 terms

pre-funded warrants financial

"pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,000,000 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"the pricing of an underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3, as amended"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of (i) 19,000,000 shares of its common stock and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,000,000 shares of its common stock, and (ii) accompanying warrants to purchase up to 21,000,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.00, and the combined offering price of each Pre-Funded Warrant to purchase one share of common stock and accompanying warrant is $0.9999, which equals the combined offering price per share of common stock and accompanying warrant, less the $0.0001 per share exercise price of each Pre-Funded Warrant. Each accompanying warrant will be exercisable for one share of common stock at an exercise price of $1.00 per share of common stock, will be exercisable immediately upon issuance and will expire five years after the date of issuance. The Pre-Funded Warrants will be exercisable immediately upon issuance and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

All of the shares of common stock, Pre-Funded Warrants and the accompanying warrants are being offered by Annovis. The shares of common stock (or Pre-Funded Warrants in lieu thereof) and the accompanying warrant will be issued separately but can only be purchased together in the offering.

Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $21.0 million, excluding potential proceeds from the exercise of the accompanying warrants. The offering is expected to close on or about November 6, 2026, subject to the satisfaction of customary closing conditions.

Canaccord Genuity is acting as the sole bookrunner in the offering.

Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in clinical studies for Alzheimer’s disease (AD) and Parkinson’s disease (PD) and for working capital and general corporate purposes.

The securities described above are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3, as amended (No. 333-276814), initially filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:

Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much does Annovis Bio expect to raise in its public offering?

Annovis expects approximately $21.0 million in gross proceeds before underwriting discounts, commissions and other offering expenses. That amount excludes potential proceeds from exercise of the accompanying warrants.

When is the Annovis Bio public offering expected to close?

The offering is expected to close on or about November 6, 2026, subject to satisfaction of customary closing conditions.

Can investors buy Annovis Bio offering shares separately from the accompanying warrants?

The common shares, or pre-funded warrants in their place, can only be purchased together with accompanying warrants in the offering. The securities will be issued separately.

When can Annovis Bio’s pre-funded warrants be exercised?

The pre-funded warrants are exercisable immediately upon issuance at $0.0001 per share and may be exercised at any time until all are exercised in full.